Report cover image

Psoriatic Arthritis - Seven-Market Drug Forecast and Market Analysis

Publisher GlobalData
Published Jun 23, 2025
Length 101 Pages
SKU # GBDT20238120

Description

Psoriatic Arthritis - Seven-Market Drug Forecast and Market Analysis

Summary


This new set to update and replace the previous psoriatic arthritis market analysis publication, Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028 (January 2020, GDHC186PIDR), which covered the forecast period 2018-28. This new publication covers the psoriatic arthritis market over the forecast period of 2023-33.

GlobalData estimated the total psoriatic arthritis market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major GlobalData estimated the value of the global PsA market to be $9.5 billion across the 7MM in 2023. By 2033, PsA sales across the markets are expected to grow to $13.5 billion, representing a compound annual growth rate (CAGR) of 3.6% over the 10-year forecast period.

Major drivers of growth in the PsA market over the forecast period include -
  • Launches of six new pipeline agents in PsA: Sotyktu (approved to treat plaque psoriasis [PsO]), icotrokinra, sonelokimab, Ilumya (approved to treat PsO), JNJ-4804, and zasokitinib.
  • Rise of small molecule therapies, both marketed and in development to treat PsA
The major barriers of growth in the PsO market during the forecast period include -
  • Loss of patent protection in the US for biologics, such as Janssen’s Stelara (ustekinumab) in 2024 and Cosentyx (secukinumab) in 2029, and the subsequent launches of their corresponding biosimilars
  • Launch of apremilast generics in 2028 in the US
  • Passage of legislature in the US, both on the federal and state level, aimed to reduce drug prices
Key Highlights
  • In 2023, GlobalData estimates that sales of drugs in the PsA market was approximately $9.5 billion in 2023 in the 7MM. The global PsA market is expected to grow to $13.5 billion in 2033, at a Compound Annual Growth Rate (CAGR) of 3.6%.
  • Major drivers of the severe market growth over the forecast period are the -
  • Launches of six new pipeline agents in PsA: Sotyktu (approved to treat plaque psoriasis [PsO]), icotrokinra, sonelokimab, Ilumya (approved to treat PsO), JNJ-4804, and zasokitinib.
  • Rise of small molecule therapies, both marketed and in development to treat PsA
Scope
  • Overview of Psoriatic Arthritis, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized psoriatic arthritis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the psoriatic arthritis therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for psoriatic arthritis treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global psoriatic arthritis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global PsA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global PsA therapeutics market from 2023-2033.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Please notethis is delivered as a Zip file.

Table of Contents

101 Pages
1 Psoriatic Arthritis: Executive Summary
1.1 Sunsetting older therapies, biosimilars, and generics dampen PsA market growth
1.2 Strategic positioning established by the PsO market
1.3 Lack of innovation provides market opportunity
1.4 Johnson & Johnson leads PsA pipeline assets with icotrokinra
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.2 Etiology
3.3 Genetic factors
3.4 Environmental and lifestyle factors
3.5 Pathophysiology
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Diagnosed incident cases of PsA
4.4.4 Diagnosed prevalent cases of PsA
4.4.5 Diagnosed prevalent cases of PsA by type
4.4.6 Diagnosed prevalent cases of PsA by severity
4.4.7 Diagnosed prevalent cases of PsA with comorbidity
4.4.8 Diagnosed prevalent cases of PsA with psoriasis
4.5 Epidemiological forecast for PsA (2023-33)
4.5.1 Diagnosed incident cases of PsA
4.5.2 Sex-specific diagnosed incident cases of PsA
4.5.3 Age-specific diagnosed incident cases of PsA
4.5.4 Diagnosed prevalent cases of PsA
4.5.5 Sex-specific diagnosed prevalent cases of PsA
4.5.6 Age-specific diagnosed prevalent cases of PsA
4.5.7 Diagnosed prevalent cases by type
4.5.8 Diagnosed prevalent cases by severity
4.5.9 Diagnosed prevalent cases by comorbidity
4.5.10 Diagnosed prevalent cases of PsA with psoriasis
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 Limitations of the analysis
4.6.3 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 Key opinion leader insights on disease management
6 Current Treatment Options
6.1 Overview
6.1.1 Tumor necrosis factor inhibitors
6.1.2 IL-17 Inhibitors
6.1.3 IL-23 Inhibitors
6.1.4 Janus kinase inhibitors
6.1.5 Other targeted synthetic disease modifying anti-rheumatic drugs
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Highly efficacious therapies
7.3 Biomarkers
7.4 Treating PsA and its comorbidities
7.5 Identifying the subclinical state of PsA
8 R&D Strategies
8.1 Overview
8.1.1 Market significant shift towards small molecules
8.1.2 Development with an eye on market positioning
8.2 Clinical trials design
8.2.1 Active comparator trials
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
9.2.1 JNJ-4804
9.2.2 Ilumya
9.2.3 Icotrokinra
9.2.4 Sonelokimab
9.2.5 Zasocitinib
9.2.6 Sotyktu
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
10.2.1 Biologic therapies
10.2.2 Small molecule therapies
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - key opinion leaders interviewed for this report
13.4.1 Key opinion leaders
13.4.2 Payers
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologist
13.6.5 Vice President of Disease Intelligence and Epidemiology
13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
13.7 Contact Us
List of Tables
Table 1: PsA: key metrics in the 7MM
Table 2: Risk factors and comorbidities for PsA
Table 3: 7MM, diagnosed prevalent cases by severity (N), men and women, ages ≥18 years, 2023
Table 4: Treatment Guidelines for PsA
Table 5: Top completed deals in PsA market by value, 2018-23
Table 6: Disease PsA market - global drivers and barriers, 2023-33
Table 7: Key events impacting sales for PsA in the US, 2023-33
Table 8: Disease PsA market - drivers and barriers in the US, 2023-2033
Table 9: Key events impacting sales for PsA in the 5EU, 2023-33
Table 10: PsA market - drivers and barriers in the 5EU, 2023-33
Table 11: Key events impacting sales for PsA in Japan, 2023-33
Table 12: PsA market - drivers and barriers in Japan, 2023-33
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for PsA in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in PsA during the forecast period
Figure 3: Competitive assessment of the marketed and pipeline biologic drugs benchmarked against the SOC, Stelara
Figure 4: Competitive assessment of the marketed and pipeline small molecules drugs benchmarked against the SOC, Rinvoq
Figure 5: 7MM, diagnosed incidence of PsA (cases per 100,000 population), men and women, ages ≥18 years, 2023
Figure 6: 7MM, diagnosed prevalence of PsA (%), men and women, ages ≥18 years, 2023
Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PsA
Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PsA
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PsA by type
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of PsA with comorbidity
Figure 11: 7MM, diagnosed incident cases of PsA (N), men and women, ages ≥18 years, 2023
Figure 12: 7MM, diagnosed incident cases of PsA by sex (N), ages ≥18 years, 2023
Figure 13: 7MM, diagnosed incident cases of PsA by age (N), men and women, 2023
Figure 14: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages ≥18 years, 2023
Figure 15: 7MM, diagnosed prevalent cases of PsA by sex (N), ages ≥18 years, 2023
Figure 16: 7MM, diagnosed prevalent cases of PsA by age (N), men and women, 2023
Figure 17: 7MM, diagnosed prevalent cases by type (N), men and women, ages ≥18 years, 2023
Figure 18: 7MM, diagnosed prevalent cases by severity (N), men and women, ages ≥18 years, 2023
Figure 19: 7MM, diagnosed prevalent cases of PsA with PsO (N), men and women, ages ≥18 years
Figure 20: Unmet needs and opportunities in PsA
Figure 21: Overview of the development pipeline in PsA
Figure 22: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PsA in the 7MM during the forecast period
Figure 23: Competitive assessment of the marketed and pipeline biologic drugs benchmarked against the SOC, Stelara
Figure 24: Competitive assessment of the marketed and pipeline small molecules drugs benchmarked against the SOC, Rinvoq
Figure 25: Analysis of the company portfolio gap in PsA during the forecast period
Figure 26: Global (7MM) sales forecast by country for PsA in 2023 and 2033
Figure 27: Sales forecast by class for PsA in the US in 2023 and 2033
Figure 28: Sales forecast by class for PsA in the 5EU in 2023 and 2033
Figure 29: Sales forecast by class for PsA in Japan in 2023 and 2033

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us